XBI:NYE-SPDR® S&P Biotech ETF (USD)

ETF | Health |

Last Closing

USD 97.51

Change

+0.87 (+0.90)%

Market Cap

N/A

Volume

5.97M

Analyst Target

N/A
Analyst Rating

N/A

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-10-04 )

Largest Industry Peers for Health

Symbol Name Price(Change) Market Cap
XLV Health Care Select Sector SPDR..

+0.12 (+0.08%)

USD 41.71B
FHLC Fidelity® MSCI Health Care In..

+0.15 (+0.21%)

USD 2.97B
FXH First Trust Health Care AlphaD..

+0.57 (+0.53%)

USD 1.23B
XHE SPDR® S&P Health Care Equipme..

+0.92 (+1.06%)

USD 0.22B
IDNA iShares Genomics Immunology an..

+0.42 (+1.74%)

USD 0.14B
SBIO ALPS Medical Breakthroughs ETF

+0.70 (+1.89%)

USD 0.11B
XHS SPDR® S&P Health Care Service..

+0.59 (+0.63%)

USD 0.08B
HTEC Robo Global® Healthcare Techn..

+0.36 (+1.25%)

USD 0.06B
BBP Virtus LifeSci Biotech Product..

+0.71 (+1.15%)

USD 0.02B
BBC Virtus LifeSci Biotech Clinica..

+0.49 (+1.80%)

USD 0.01B

ETFs Containing XBI

MATH Metalpha Technology Holdi.. 0.00 % 1.35 %

N/A

USD 0.04B
INAV 0.00 % 0.00 %

N/A

N/A

Market Performance

  Market Performance vs. Industry/Classification (Health) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 9.21% 57% F 53% F
Dividend Return 0.15% 19% F 2% F
Total Return 9.35% 57% F 45% F
Trailing 12 Months  
Capital Gain 35.00% 90% A- 80% B-
Dividend Return 0.20% 17% F 2% F
Total Return 35.20% 90% A- 76% C+
Trailing 5 Years  
Capital Gain 26.93% 33% F 58% F
Dividend Return 0.56% 28% F 2% F
Total Return 27.49% 29% F 49% F
Average Annual (5 Year Horizon)  
Capital Gain 2.38% N/A N/A 47% F
Dividend Return 2.46% N/A N/A 37% F
Total Return 0.08% N/A N/A 3% F
Risk Return Profile  
Volatility (Standard Deviation) 32.87% N/A N/A 30% F
Risk Adjusted Return 7.50% N/A N/A 29% F
Market Capitalization N/A N/A N/A N/A N/A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:

There is nothing we particularly like

What to not like:

There is nothing we particularly dislike